Stay updated with breaking news from Dave knopman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
More than 2 years after its controversial accelerated FDA approval, Biogen says it will halt development and commercialization of aducanumab and focus on lecanemab. ....